Eagle Pharmaceuticals to Host Second Quarter 2023 Financial Results on August 8, 2023
01 Agosto 2023 - 7:50AM
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq:
EGRX) today announced that the Company will release its second
quarter 2023 financial results on Tuesday, August 8, 2023, before
the market opens.
Scott Tarriff, President and Chief Executive Officer, and Brian
Cahill, Chief Financial Officer, will host a conference call to
discuss the results as follows:
Date |
Tuesday, August 8, 2023 |
Time |
8:30 a.m. ET |
Toll free (U.S.) |
800-343-4136 |
International |
203-518-9814 |
Webcast (live and replay) www.eagleus.com, under the
“Investor Relations” section
A replay of the conference call will be available for two weeks
after the call's completion by dialing 800-839-9409 (U.S.) or
402-220-6088 (International) and entering conference call ID
EGRXQ223. The webcast will be archived for 30 days at the
aforementioned URL.
About Eagle Pharmaceuticals,
Inc. Eagle is a fully integrated
pharmaceutical company with research and development, clinical,
manufacturing and commercial expertise. Eagle is committed to
developing innovative medicines that result in meaningful
improvements in patients’ lives. Eagle’s commercialized products
include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®,
TREAKISYM® (Japan), and BYFAVO® and
BARHEMSYS® through its wholly owned subsidiary Acacia Pharma
Inc. Eagle’s oncology and CNS/metabolic critical care pipeline
includes product candidates with the potential to address
underserved therapeutic areas across multiple disease states.
Additional information is available on Eagle’s website
at www.eagleus.com.
Contact:Investor Relations for Eagle
Pharmaceuticals, Inc:Lisa M. WilsonT: 212-452-2793E:
lwilson@insitecony.com
Eagle Pharmaceuticals (NASDAQ:EGRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024